Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, [(1R,7aR)-2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl]methyl ester, (2S,3R)- - Names and Identifiers
Name | Intermedine
|
Synonyms | C10330 Intermedine INTERMIDINE (+)-Intermedine 9-(+)-Trachelanthylretronecine (1R)-2,3,5,7aβ-Tetrahydro-7-[[(2S,3R)-2-isopropyl-2,3-dihydroxybutyryl]oxymethyl]-1H-pyrrolizine-1-ol (2S,3R)-2,3-Dihydroxy-2-isopropylbutanoic acid [[(5R,6R)-6-hydroxy-1-azabicyclo[3.3.0]oct-3-en-4-yl]methyl] ester Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, [(1R,7aR)-2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl]methyl ester, (2S,3R)-
|
CAS | 10285-06-0
|
Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, [(1R,7aR)-2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl]methyl ester, (2S,3R)- - Physico-chemical Properties
Molecular Formula | C15H25NO5
|
Molar Mass | 299.36 |
Density | 1.26±0.1 g/cm3(Predicted) |
Melting Point | 140-141 °C |
Boling Point | 463.3±45.0 °C(Predicted) |
pKa | 12.59±0.29(Predicted) |
Storage Condition | -20℃ |
Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, [(1R,7aR)-2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl]methyl ester, (2S,3R)- - Risk and Safety
UN IDs | 1544 |
Hazard Class | 6.1(b) |
Packing Group | III |
Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, [(1R,7aR)-2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl]methyl ester, (2S,3R)- - Introduction
Intermedine(Intermedin) is a protein hormone that is encoded by the gene PTN in the human body. It achieves its biological activity in vivo primarily by binding to its receptors (CALCRL and RAMP2). Intermedine plays an important regulatory role in many physiological processes, such as vasodilation, cell proliferation, anti-oxidation and reduction of fibrosis.
Intermedine has a variety of applications. It is studied in the medical field for the treatment of cardiovascular diseases such as hypertension, heart failure and myocardial infarction. In addition, studies have shown that Intermedine may have an inhibitory effect on tumor growth, so it is also used in cancer treatment research.
The preparation method of Intermedine is generally synthesized by genetic engineering technology. By introducing Intermedine-related genes in the human body into appropriate host cells (such as bacteria or yeast), and then using expression and purification techniques to obtain pure Intermedine proteins.
There is a lack of complete research on the safety of Intermedine. However, preliminary studies have shown that Intermedine rarely presents serious safety concerns when used to treat cardiovascular disease and cancer. However, there may be differences in individual responses to Intermedine, so it is best to consult a professional doctor's advice before use and follow the doctor's instructions for use. In general, for any chemical, rational use and compliance with appropriate dosage and usage are key to ensuring safety.
Last Update:2024-04-09 20:52:54